Patients with type 2 diabetes and CKD are at high risk for cardiovascular disease and kidney failure. Studies have found that significant beneficial effects on kidney function and renal outcomes were seen with treatment by Ozempic. Fewer people showed a persistent drop in estimated glomerular filtration rate (eGFR), which is a test that measures levels of kidney function and determines the stage of kidney disease. People with pre-existing kidney disease achieved a significantly slower annual loss of kidney function compared to those receiving a placebo.